Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial

The introduction of immune checkpoint inhibitors has transformed the treatment landscape of metastatic non‐small cell lung cancer. However, challenges remain to increase the fraction of patients achieving durable clinical responses to these drugs and to help monitor the treatment effect. In this pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Horndalsveen, Henrik, Alver, Tine Norman, Dalsgaard, Astrid Marie, Rogg, Lotte Victoria, Helbekkmo, Nina, Grønberg, Bjørn Henning, Halvorsen, Tarje Onsøien, Ramberg, Christina, Haakensen, Vilde Drageset, Öjlert, Åsa Kristina, Bjaanæs, Maria Moksnes, Helland, Åslaug
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980306/
https://www.ncbi.nlm.nih.gov/pubmed/36330681
http://dx.doi.org/10.1002/1878-0261.13330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980306/
https://www.ncbi.nlm.nih.gov/pubmed/36330681
http://dx.doi.org/10.1002/1878-0261.13330

Ejemplares similares